MADISON, Wis. – July 24, 2026
Elephas Biosciences Corporation has unveiled new preclinical data demonstrating that its elive™ functional precision medicine platform can measure cytotoxicity endpoints for targeted cancer therapies, significantly expanding the platform beyond its previously established capabilities in immunotherapy response prediction. Presented at the American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference, the findings show that the platform can accurately evaluate responses to both immune checkpoint inhibitors (ICIs) and targeted therapies using live tumor tissue. The announcement comes shortly after the American Society of Clinical Oncology (ASCO) formally recognized functional precision medicine as an emerging approach to improve personalized cancer treatment, positioning the elive™ platform as a promising diagnostic tool for guiding future oncology treatment decisions.
New Data Demonstrate Broader Functional Precision Medicine Capabilities
The study, titled “Evaluation of immune checkpoint inhibitors and targeted therapies ex vivo in live tumor fragments from core biopsies and resections accurately predicts response in the clinic,” was presented by Sean Caenepeel, Vice President of Medical Affairs at Elephas Biosciences. Researchers generated data using mouse xenograft models and live human tumor tissue samples, evaluating responses to the targeted therapy daraxonrasib. Results showed that ex vivo treatment produced comparable cytotoxic effects across both preclinical and human tissue models, suggesting that the platform’s predictive performance can successfully translate from laboratory research to clinical patient samples. The findings expand the platform’s ability to evaluate multiple treatment classes while preserving the native tumor microenvironment, a critical factor in accurately assessing therapeutic response.
ASCO Recognition Reinforces Growing Role of Functional Testing
The presentation coincides with increasing industry recognition of functional precision medicine, following ASCO’s recent clinical notice supporting the approach as an important advancement in personalized oncology care. Unlike conventional biomarker-based diagnostics, functional precision medicine directly measures how a patient’s living tumor responds to treatment before therapy begins. Elephas Biosciences believes its elive™ platform is among the first technologies supported by evidence across both immune checkpoint inhibitors and targeted cancer therapies, strengthening its potential role in future clinical decision-making. According to Founder and CEO Maneesh Arora, the platform builds upon previous evidence demonstrating immunotherapy response prediction while now extending its capabilities to targeted therapies, representing an important milestone in oncology diagnostics.
Advertisement
Live Tissue Platform Aims to Improve Personalized Cancer Care
Elephas Biosciences developed the elive™ platform to address one of oncology’s greatest challenges—accurately predicting which patients will respond to specific cancer therapies. The technology analyzes live core needle biopsy samples while preserving the tumor microenvironment, enabling real-time evaluation of immune activity and treatment response. This approach seeks to overcome limitations of current predictive biomarkers, particularly in immunotherapy, where only a minority of patients achieve meaningful clinical benefit. By expanding the platform to include targeted therapies, Elephas Biosciences is advancing a broader functional precision medicine strategy that could help physicians make more informed treatment decisions, improve patient outcomes, and reduce unnecessary exposure to ineffective cancer therapies as personalized oncology continues to evolve.
Source: Elephas Biosciences press release
